Christopher P Kellner, MD Email Christopher Kellner
- ASSISTANT PROFESSOR | Neurosurgery
- Hospital Affiliations
- Mount Sinai Brooklyn
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- Mount Sinai Queens
- Mount Sinai Morningside and Mount Sinai West
Christopher Kellner, MD, is an Assistant Professor in Neurosurgery specializing in the endovascular and minimally invasive treatment of different forms of stroke, aneurysms, arteriovenous malformations, dural arteriovenous fistulas, cavernous malformations, and other vascular problems of the brain and spine. He is Director of the Intracerebral Hemorrhage Program and Principal Investigator of the Cerebrovascular Translational Laboratory and serves as Associate Director of the Neurosurgery Residency Program.
Dr. Kellner received his undergraduate degree from Harvard University and earned his medical degree from the College of Physicians & Surgeons at Columbia University. He also completed his neurosurgery residency training at NewYork-Presbyterian/Columbia University Medical Center. He then performed his endovascular fellowship at Mount Sinai with Drs. Alejandro Berenstein, J Mocco, Johanna Fifi, and Reade De Leacy.
Dr. Kellner has authored over 60 peer-reviewed publications and 10 book chapters. His research focuses on improving outcomes in endoscopic minimally invasive intracerebral hemorrhage evacuation, decreasing brain inflammation after stroke, early diagnosis of stroke, and early diagnosis of cerebral aneurysms. He is the principal investigator of the VITAL study, a multicenter clinical trial evaluating the VIPS device, which is a non-invasive, portable, easy-to-use severe stroke detection device that can be used in the ambulance to correctly diagnose severe stroke to triage patients to the right hospital.
Dr. Kellner believes that the patient-doctor relationship is built on a foundation of understanding that comes from education, trust, and accessibility. He uses 3D models and virtual reality whenever possible to describe complex procedures to his patients. He also uses these technologies to rehearse a surgery prior to the real thing.
Precision Recovery - Fight Against Coronavirus Pandemic
In the fight against the coronavirus pandemic, Mount Sinai Health System announced a new remote monitoring platform to help provide care and monitor COVID-19 patients who are recuperating at home, Precision Recovery Platform. Dr. Kellner co-developer of the platform, said the technology will play a "massive role" in the crisis. The database was originally used for stroke victims but has been adapted for COVID-19 patients whose symptoms are not severe enough to be hospitalized.
Read about how Dr. Kellner adapted Precision Recovery to help more than 800 COVID-19 patients in the 2020 Neurology & Neurosurgery Specialty Report.
In the News
Christopher Kellner, MD is a Dedicated Mentor to Students of all Levels (Fox News)
Christopher Kellner, MD is a PI of a Multicentered Trial, Evaluating New Technology, Cerebrotech Visor, to Detect and Triage Stroke (CBS News)
Christopher Kellner, MD is Co-Director to Mount Sinai's Remote Coronavirus Monitoring (Fox News)
- Aneurysm Coiling
- Arteriovenous Malformation of the Brain
- Brain Aneurysm
- Carotid Artery Stenosis
- Carotid Stenting
- Cavernous Malformations
- Cerebral Vasospasm
- Cerebrospinal Fluid Leak
- Dural Arteriovenous Fistula (DAVF)
- Endovascular Embolization
- Facial Arteriovenous Malformations
- Facial Vascular Malformations
- Intracerebral Hemorrhage (ICH)
- Mechanical Thrombectomy
- Microvascular Clipping
- Microvascular Occlusion
- Spinal Vascular Malformations
- Stereotactic Radiosurgery
- Subarachnoid Hemorrhage
- Subdural Hematoma
- Vascular Malformations
- Venous Sinus Thrombosis
Regeneration, Rehabilitation, Stem Cells, Stroke
MD, Columbia University College of Physicians & Surgeons
New York Presbyterian / Columbia University
Fellowship, Endovascular Intervention/Peripheral
The Mount Sinai Hospital
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Kellner during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Metis Innovative, LLC
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Metis Innovative, LLC
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Fluid Biotech
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.